Inspire Medical Soars: Q2 Revenue Up 26.5%, Swings to Profit

TL;DR

INSP is crushing it, swinging to profit with massive revenue growth – buy the dip if you can find one.

AI Summary

Inspire Medical Systems, Inc. reported robust financial performance for the second quarter ended June 30, 2025, with revenue reaching $192.5 million, marking a significant 26.5% increase compared to $152.2 million in the same period of 2024. The company achieved a net income of $15.3 million for Q2 2025, a substantial improvement from a net loss of $2.1 million in Q2 2024. For the six months ended June 30, 2025, total revenue grew to $365.8 million, up 28.1% from $285.5 million in the prior year, and net income was $22.7 million, a turnaround from a net loss of $10.5 million in the first half of 2024. Key business changes include continued expansion of their Inspire therapy, with U.S. revenue increasing by 27.1% to $183.4 million in Q2 2025. The company's strategic outlook remains focused on market penetration and operational efficiency, as evidenced by a gross margin of 83.9% for Q2 2025. Risks include increased operating expenses, which rose to $146.7 million in Q2 2025 from $128.4 million in Q2 2024, primarily due to higher personnel-related expenses and clinical trial costs.

Why It Matters

Inspire Medical Systems' strong Q2 2025 performance, particularly its swing to a $15.3 million net profit from a $2.1 million loss, signals growing market acceptance and operational efficiency for its sleep apnea therapy. This positive trajectory could attract more investors, potentially driving stock value, and provides job security and growth opportunities for its 2,000+ employees. For customers, the expanding reach and profitability suggest continued innovation and accessibility of the Inspire therapy, while in the competitive landscape, this solidifies Inspire's position against other medical device companies in the sleep apnea treatment market.

Risk Assessment

Risk Level: medium — While revenue and net income show strong growth, the company's operating expenses increased by 14.2% to $146.7 million in Q2 2025, primarily driven by higher personnel-related expenses and clinical trial costs. This sustained increase in expenses could pressure future profitability if revenue growth decelerates, indicating a medium risk profile despite current strong performance.

Analyst Insight

Investors should consider holding or initiating a position in INSP, given the strong revenue growth of 26.5% and the significant swing to a net profit of $15.3 million in Q2 2025. Monitor operating expense growth relative to revenue to ensure profitability remains sustainable.

Financial Highlights

revenue

$192.5M

net Income

$15.3M

gross Margin

83.9%

revenue Growth

+26.5%

Revenue Breakdown

Key Numbers

• $192.5M — Q2 2025 Revenue (Increased 26.5% from Q2 2024)
• $15.3M — Q2 2025 Net Income (Swung from a $2.1M net loss in Q2 2024)
• 26.5% — Q2 Revenue Growth (Year-over-year increase for Q2 2025)
• 28.1% — Six-Month Revenue Growth (Year-over-year increase for the first half of 2025)
• 83.9% — Gross Margin (Achieved in Q2 2025, indicating strong profitability per sale)
• $183.4M — U.S. Revenue Q2 2025 (Increased 27.1% from Q2 2024, showing strong domestic growth)
• $146.7M — Q2 2025 Operating Expenses (Increased 14.2% from Q2 2024, driven by personnel and clinical costs)

Key Players & Entities

• Inspire Medical Systems, Inc. (company) — filer of the 10-Q
• $192.5 million (dollar_amount) — total revenue for Q2 2025
• $152.2 million (dollar_amount) — total revenue for Q2 2024
• $15.3 million (dollar_amount) — net income for Q2 2025
• $2.1 million (dollar_amount) — net loss for Q2 2024
• $365.8 million (dollar_amount) — total revenue for the six months ended June 30, 2025
• $285.5 million (dollar_amount) — total revenue for the six months ended June 30, 2024
• $22.7 million (dollar_amount) — net income for the six months ended June 30, 2025
• $10.5 million (dollar_amount) — net loss for the six months ended June 30, 2024
• $146.7 million (dollar_amount) — operating expenses for Q2 2025

FAQ

Risk Factors

• Increased Operating Expenses [medium — operational]: Operating expenses rose to $146.7 million in Q2 2025 from $128.4 million in Q2 2024. This increase is primarily attributed to higher personnel-related expenses and costs associated with clinical trials, impacting overall profitability.
• Market Penetration Challenges [medium — market]: While revenue growth is robust, continued expansion of Inspire therapy requires significant investment in sales and marketing. Competition and the need for physician adoption present ongoing market penetration challenges.
• Regulatory Compliance [high — regulatory]: As a medical device company, Inspire Medical Systems is subject to stringent regulatory oversight from bodies like the FDA. Changes in regulations or failure to maintain compliance could impact product development, manufacturing, and market access.

Industry Context

Inspire Medical Systems operates in the rapidly evolving medical device sector, specifically focusing on sleep apnea treatment. The market is characterized by technological innovation and a growing demand for less invasive solutions. Key competitors include traditional CPAP manufacturers and other emerging implantable device companies.

Regulatory Implications

As a medical device manufacturer, Inspire Medical Systems is subject to rigorous FDA regulations for product approval, manufacturing, and post-market surveillance. Any changes in regulatory requirements or compliance issues could significantly impact the company's ability to market and sell its products.

What Investors Should Do

1. Monitor operating expense growth
2. Assess international expansion strategy
3. Evaluate clinical trial progress and outcomes

Glossary

10-Q

A quarterly report required by the U.S. Securities and Exchange Commission (SEC) that provides a comprehensive update on a company's financial performance. (This document provides the detailed financial information and operational updates for Inspire Medical Systems for the second quarter of 2025.)

Gross Margin

The difference between revenue and cost of goods sold, expressed as a percentage. It indicates the profitability of a company's products before accounting for operating expenses. (Inspire Medical Systems reported a strong gross margin of 83.9% in Q2 2025, highlighting efficient production and pricing power.)

Operating Expenses

Costs incurred by a company in its normal course of business, excluding the cost of goods sold. This includes expenses like research and development, sales and marketing, and general and administrative costs. (The increase in operating expenses to $146.7 million in Q2 2025 is a key factor impacting the company's bottom line and requires monitoring.)

Year-Over-Year Comparison

Inspire Medical Systems demonstrated significant year-over-year improvement in its Q2 2025 results compared to Q2 2024. Revenue increased by 26.5% to $192.5 million, and the company swung from a net loss of $2.1 million to a net income of $15.3 million. While gross margins remained strong at 83.9%, operating expenses also saw an increase of 14.2% to $146.7 million, driven by investments in personnel and clinical trials.

Filing Details

This Form 10-Q (Form 10-Q) was filed with the SEC on August 4, 2025 regarding Inspire Medical Systems, Inc. (INSP).

View full filing on EDGAR

View Full Filing

View this 10-Q filing on SEC EDGAR